IBEX 35
11.067,80 +150,30 (+1,38%) Euro Stoxx 50
4.998,94 +41,98 (+0,85%) Dólar/Euro
1,0779 +0,0006 (+0,05%) Petróleo Brent
82,73 -0,60 (-0,72%) Oro
2.329,70 -1,50 (-0,06%) Bitcoin EUR
58.738,55 -758,48 (-1,27%)
CSPC Pharmaceutical Group Limited (1093.HK)
CSPC Pharmaceutical Group Limited
No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
https://www.cspc.com.hk
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 23.500
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Dongchen Cai | Executive Chairman | 19,98M | N/A | 1954 |
| Mr. Cuilong Zhang | Vice-Chairman & CEO | 10,62M | N/A | 1969 |
| Mr. Chunlei Li | Executive Director & Chief Scientist | 7,23M | N/A | 1976 |
| Mr. Kin Man Chak | Executive Director | 5,29M | N/A | 1966 |
| Mr. Weidong Pan | Executive Director | 3,84M | N/A | 1969 |
| Mr. Huaiyu Wang | Executive Director | 4,72M | N/A | 1963 |
| Mr. Zhenguo Wang | Executive Director | 3,82M | N/A | 1970 |
| Dr. Qingxi Wang Ph.D. | Executive Director | 3,34M | N/A | 1966 |
| Dr. Hao Jiang | Executive Director | 2,87M | N/A | 1984 |
Descripción
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Gobierno corporativo
El ISS Governance QualityScore de CSPC Pharmaceutical Group Limited, a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 6; Derechos de los accionistas: 4; Compensación: 9.
